Cannabidiol/nabiximols/warfarin interaction
- PDF / 169,760 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 93 Downloads / 173 Views
1 XS
Cannabidiol/nabiximols/warfarin interaction Increased INR following the concomitant administration of cannabidiol, nabiximols or warfarin : 2 case reports
In a case series, a 76-year-old woman and an 83-year-old man were described, who showed increased INR following the concomitant administration of cannabidiol, nabiximols or warfarin. Both the cases were reported to the Health Canada [routes and indications not stated; not all dosages and durations of treatments to reactions onsets stated]. Case 1: A 76-year-old woman showed increased INR following the concomitant administration of cannabidiol and warfarin. The woman started receiving receiving warfarin and cannabidiol oil (exact brand and concentration not stated). She showed increased INR (4.8) less than one week after starting cannabidiol oil. As per the reporter, the cause of her increased INR could be the initiation of the cannabidiol oil. The possible cause for the increased INR was proposed as the potential pharmacokinetic interaction between cannabidiol and warfarin. Therefore, cannabidiol was stopped and warfarin dose was adjusted. Thereafter, her INR was found to be within the therapeutic range. Case 2: An 83-year-old man showed increased INR following the concomitant administration of nabiximols and warfarin. The man had been receiving warfarin and nabiximols oil [1 mg/mL tetrahydrocannabinol/20 mg/mL cannabidiol]. He showed increased INR (6.2) approximately 3 months after starting nabiximols oil. The possible cause for the increased INR was proposed as the potential pharmacokinetic interaction between nabiximols and warfarin. Therefore, nabiximols was stopped and warfarin dose was adjusted. Thereafter, his INR was found to be within the therapeutic range. Health Product InfoWatch. Cannabis and warfarin-Potential drug interaction Health Product InfoWatch : 4-7, 4 Nov 2020. Available from: URL: https://www.canada.ca/ content/dam/hc-sc/documents/services/drugs-health-products/medeffect-canada/health-product-infowatch/health-product-infowatch-october-2020/health-product-infowatch803514775 october-2020-eng.pdf
0114-9954/20/1830-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 14 Nov 2020 No. 1830
Data Loading...
